Drugs / trivalent split influenza vaccine
trivalent split influenza vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT00498303 | Jun 2007 → ? | influenza | Novartis | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00776750 | Sep 2003 → May 2004 | — | Universitaire Ziekenhuizen KU Leuven | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT01346592 Comparator | Apr 2011 → Jul 2012 | influenza | Novartis Vaccines | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | trivalent split influenza vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00498303 ↗ |
| Known as | TIV | “Trivalent split influenza vaccine (TIV)” NCT01346592 ↗ |
| Known as | Vaxigrip | “standard dose of 0.5 ml commercially available trivalent split influenza vaccine (Vaxigrip®, Aventis Pasteur MSD) by intramuscular injection” NCT00776750 ↗ |
| Modality | Vaccine | “trivalent split influenza vaccine” NCT00498303 ↗ |
| Route | Intramuscular | “by intramuscular injection” NCT00776750 ↗ |